Throughout the end of 2026, new indications across a broad range of clinical applications are expected that employers should be aware of, including: ALZHEIMERS DISEASE Semaglutide could become the first GLP-1 drug approved for Alzheimer's disease (AD) by late 2026
Placing three substances in one vial creates a preparation with no literature of its own, assembled from three literatures that were never designed to be combined
Exposure to irritating chemicals The primary culprit is cigarette smoke, even secondhand cigarette smoke
Each plasma center operates under FDA guidelines but maintains its own specific donor policies
Biomimetic particles as therapeutics
"To be able to get this, if indeed that's what it is who knows what it really is." A tricky new world for physicians At the popular testosterone and hormone clinic Gameday Men's Health, chief medical officer Dr